The nicotinamide adenine dinucleotide market is primed to grow massively through 2030 owing to shifting beauty standards across the world. In addition, burgeoning instances of chronic diseases, along with the thriving pharmaceutical industry, are likely to augment market growth over the forecast period.

The COVID-19 pandemic encouraged business owners to secure and sustain their supply networks in order to cater to rising product demand. However, advancements in NAD supplements and products, coupled with rising awareness pertaining to product benefits, bolstered product deployment in the cosmetics and pharmaceutical industries.

Moreover, key participants in the nicotinamide adenine dinucleotide market majorly engage in expanding the range of products and undertaking extensive R&D projects to remain ahead in the competitive landscape, thereby fuelling overall business growth. In October 2022, ChromaDex, a specialist in dietary supplements, published the results of a clinical study on the safety and tolerability of NAD+ precursor nicotinamide riboside (NR). The findings indicated that NR was able to raise NAD+ levels, emerging as a novel heart failure treatment with decreased ejection fraction.

The nicotinamide adenine dinucleotide market has been categorized on the basis of grade, application, and region.

Based on grade, the nicotinamide adenine dinucleotide industry has been divided into food grade, pharmaceutical grade, and others. The food-grade NAD segment is slated to amass substantial gains over 2022-2030 as a result of various advantages of NAD supplementation, such as increased immunity & energy, improved memory, and lower blood pressure & cholesterol.

With respect to application, the NAD market has been classified into dietary supplements, pharmaceuticals, anti-aging products, and others. The others application segment is poised to witness strong growth at over 11.5% CAGR by 2030. Other applications of NAD include its use as a biochemical assay, as a cofactor in research, and so on.

In in-vitro diagnostics, nicotinamide adenine dinucleotide is used for non-glucose target detection with the use of NAD dependent enzymes. Growing consumer awareness and acceptance of NAD-based products for analytical applications is speculated to accelerate the growth of the segment.

In the regional context, the Middle East & Africa NAD industry is anticipated to expand at more than 10% CAGR between 2022 and 2030. Enhanced food and beverage production, new technological developments, and the launch of innovative nutraceutical products in the MEA region are set to drive market progress.

Meanwhile, the Latin America nicotinamide adenine dinucleotide market is projected to depict over 10.5% CAGR over the next 8 years. Favorable foreign direct investments and trade policies in the pharmaceutical sector, together with advancements in the food & beverage industry, are foreseen to foster the LATAM nicotinamide adenine dinucleotide industry outlook.